Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Research article

Modeling to capture bystander-killing effect by released payload in target positive tumor cells

Authors: Jong Hyuk Byun, Il Hyo Jung

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Antibody-drug conjugates (ADCs) are intended to bind to specific positive target antigens and eradicate only tumor cells from an intracellular released payload through the lysosomal protease. Payloads, such as MMAE, have the capacity to kill adjacent antigen-negative (Ag–) tumor cells, which is called the bystander-killing effect, as well as directly kill antigen-positive (Ag+) tumor cells. We propose that a dose-response curve should be independently considered to account for target antigen-positive/negative tumor cells.

Methods

A model was developed to account for the payload in Ag+/Ag– cells and the associated parameters were applied. A tumor growth inhibition (TGI) effect was explored based on an ordinary differential equation (ODE) after substituting the payload concentration in Ag+/Ag– cells into an Emax model, which accounts for the dose-response curve. To observe the bystander-killing effects based on the amount of Ag+/Ag– cells, the Emax model is used independently. TGI models based on ODE are unsuitable for describing the initial delay through a tumor–drug interaction. This was solved using an age-structured model based on the stochastic process.

Results

β∈(0,1] is a fraction parameter that determines the proportion of cells that consist of Ag+/Ag– cells. The payload concentration decreases when the ratio of efflux to influx increases. The bystander-killing effect differs with varying amounts of Ag+ cells. The larger β is, the less bystander-killing effect. The decrease of the bystander-killing effect becomes stronger as Ag+ cells become larger than the Ag– cells. Overall, the ratio of efflux to influx, the amount of released payload, and the proportion of Ag+ cells determine the efficacy of the ADC. The tumor inhibition delay through a payload-tumor interaction, which goes through several stages, may be solved using an age-structured model.

Conclusions

The bystander-killing effect, one of the most important topics of ADCs, has been explored in several studies without the use of modeling. We propose that the bystander-killing effect can be captured through a mathematical model when considering the Ag+ and Ag– cells. In addition, the TGI model based on the age-structure can capture the initial delay through a drug interaction as well as the bystander-killing effect.
Appendix
Available only for authorised users
Literature
1.
go back to reference Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. Antibody–drug conjugates: current status and future directions. Drug Discov Today. 2014; 19(7):869–81.PubMed Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. Antibody–drug conjugates: current status and future directions. Drug Discov Today. 2014; 19(7):869–81.PubMed
2.
go back to reference Bender B, Leipold DD, Xu K, Shen B-Q, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody–drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 2014; 16(5):994–1008.PubMedPubMedCentral Bender B, Leipold DD, Xu K, Shen B-Q, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody–drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 2014; 16(5):994–1008.PubMedPubMedCentral
3.
go back to reference Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7):631–7.PubMed Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7):631–7.PubMed
4.
go back to reference Wang J, Shen W-C, Zaro JL. Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer, Vol. 17.Switzerland: Springer; 2015. Wang J, Shen W-C, Zaro JL. Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer, Vol. 17.Switzerland: Springer; 2015.
5.
go back to reference Chari RVJ, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie S, Goldmacher VS. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992; 52 1:127–31. Chari RVJ, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie S, Goldmacher VS. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992; 52 1:127–31.
6.
go back to reference Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law C-L. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016; 76(9):2710–9.PubMed Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law C-L. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016; 76(9):2710–9.PubMed
7.
go back to reference Macheras P, Iliadis A. Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics: Homogeneous and Heterogeneous Approaches. Interdisciplinary Applied Mathematics. Switzerland: Springer International Publishing; 2016. Macheras P, Iliadis A. Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics: Homogeneous and Heterogeneous Approaches. Interdisciplinary Applied Mathematics. Switzerland: Springer International Publishing; 2016.
8.
go back to reference Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010; 10(5):345.PubMed Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010; 10(5):345.PubMed
9.
go back to reference Meibohm B, Derendorf H. Basic concepts of pharmacokinetic pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997; 35(10):401–13.PubMed Meibohm B, Derendorf H. Basic concepts of pharmacokinetic pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997; 35(10):401–13.PubMed
10.
go back to reference Johnson KA, Goody RS. The Original Michaelis Constant: Translation of the 1913 Michaelis–Menten Paper. Biochemistry. 2011; 50(39):8264–9.PubMedPubMedCentral Johnson KA, Goody RS. The Original Michaelis Constant: Translation of the 1913 Michaelis–Menten Paper. Biochemistry. 2011; 50(39):8264–9.PubMedPubMedCentral
11.
go back to reference Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T. Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models. Drug Metab Dispos. 2008; 36(7):1267–74.PubMed Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T. Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models. Drug Metab Dispos. 2008; 36(7):1267–74.PubMed
12.
go back to reference Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012; 39(6):643–59.PubMed Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012; 39(6):643–59.PubMed
13.
go back to reference Thurber GM, Weissleder R. A systems approach for tumor pharmacokinetics. PloS ONE. 2011; 6(9):24696. Thurber GM, Weissleder R. A systems approach for tumor pharmacokinetics. PloS ONE. 2011; 6(9):24696.
14.
go back to reference Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PloS ONE. 2011; 6(4):17887. Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PloS ONE. 2011; 6(4):17887.
15.
go back to reference Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK. Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (t-dm1). AAPS J. 2016; 18(4):861–75.PubMedPubMedCentral Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK. Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (t-dm1). AAPS J. 2016; 18(4):861–75.PubMedPubMedCentral
16.
go back to reference Khera E, Cilliers C, Bhatnagar S, Thurber GM. Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy. Mol Syst Des Eng. 2018; 3(1):73–88. Khera E, Cilliers C, Bhatnagar S, Thurber GM. Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy. Mol Syst Des Eng. 2018; 3(1):73–88.
17.
go back to reference Vasalou C, Helmlinger G, Gomes B. A mechanistic tumor penetration model to guide antibody drug conjugate design. PloS ONE. 2015; 10(3):0118977. Vasalou C, Helmlinger G, Gomes B. A mechanistic tumor penetration model to guide antibody drug conjugate design. PloS ONE. 2015; 10(3):0118977.
18.
go back to reference Vaidya VG, Alexandro FJ. Evaluation of some mathematical models for tumor growth. nt J Biomed Comput. 1982; 13(1):19–35. Vaidya VG, Alexandro FJ. Evaluation of some mathematical models for tumor growth. nt J Biomed Comput. 1982; 13(1):19–35.
19.
go back to reference Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?Br J Cancer. 2017; 117(12):1736.PubMedPubMedCentral Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?Br J Cancer. 2017; 117(12):1736.PubMedPubMedCentral
20.
go back to reference Tai Y-T, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128–38.PubMedPubMedCentral Tai Y-T, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128–38.PubMedPubMedCentral
21.
go back to reference Kakizoe Y, Nakaoka S, Beauchemin CA, Morita S, Mori H, Igarashi T, Aihara K, Miura T, Iwami S. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic shiv strain. Sci Rep. 2015; 5:10371.PubMedPubMedCentral Kakizoe Y, Nakaoka S, Beauchemin CA, Morita S, Mori H, Igarashi T, Aihara K, Miura T, Iwami S. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic shiv strain. Sci Rep. 2015; 5:10371.PubMedPubMedCentral
22.
go back to reference Mittler JE, Sulzer B, Neumann AU, Perelson AS. Influence of delayed viral production on viral dynamics in HIV-1 infected patients. Math Biosci. 1998; 152(2):143–63.PubMed Mittler JE, Sulzer B, Neumann AU, Perelson AS. Influence of delayed viral production on viral dynamics in HIV-1 infected patients. Math Biosci. 1998; 152(2):143–63.PubMed
23.
go back to reference Angstmann CN, Erickson AM, Henry BI, McGann AV, Murray JM, Nichols JA. Fractional order compartment models. SIAM J Appl Math. 2017; 77(2):430–46. Angstmann CN, Erickson AM, Henry BI, McGann AV, Murray JM, Nichols JA. Fractional order compartment models. SIAM J Appl Math. 2017; 77(2):430–46.
24.
go back to reference Mittler JE, Sulzer B, Neumann AU, Perelson AS. Influence of delayed viral production on viral dynamics in HIV-1 infected patients. Math Biosci. 1998; 152(2):143–63.PubMed Mittler JE, Sulzer B, Neumann AU, Perelson AS. Influence of delayed viral production on viral dynamics in HIV-1 infected patients. Math Biosci. 1998; 152(2):143–63.PubMed
25.
go back to reference Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol. 2006; 80(15):7590–9.PubMedPubMedCentral Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol. 2006; 80(15):7590–9.PubMedPubMedCentral
26.
go back to reference Johnson NL, Kotz S, Balakrishnan N. Continuous Univariate Distributions. Wiley series in probability and mathematical statistics: Applied probability and statistics. New York: Wiley; 1995. Johnson NL, Kotz S, Balakrishnan N. Continuous Univariate Distributions. Wiley series in probability and mathematical statistics: Applied probability and statistics. New York: Wiley; 1995.
27.
go back to reference Allen AO. Probability, Statistics, and Queuing Theory with Computer Science Applications, 2nd edn. Computer Science and Scientific Computing. San Diego: Academic Press; 1990, pp. 665–714. Allen AO. Probability, Statistics, and Queuing Theory with Computer Science Applications, 2nd edn. Computer Science and Scientific Computing. San Diego: Academic Press; 1990, pp. 665–714.
28.
go back to reference Alley SC, Okeley NM, Senter PD. Curr Opin Chem Biol. 2010; 14(4):529–37. Alley SC, Okeley NM, Senter PD. Curr Opin Chem Biol. 2010; 14(4):529–37.
29.
go back to reference Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu S-F, Mai E, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012; 30(2):184–9.PubMed Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu S-F, Mai E, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012; 30(2):184–9.PubMed
30.
go back to reference Byun JH, Jung IH. Mathematical modeling of antibody drug conjugates with the target and tubulin dynamics to predict AUC. J Theor Biol. 2018; 443:113–24.PubMed Byun JH, Jung IH. Mathematical modeling of antibody drug conjugates with the target and tubulin dynamics to predict AUC. J Theor Biol. 2018; 443:113–24.PubMed
31.
go back to reference Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28(6):507–32.PubMed Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28(6):507–32.PubMed
Metadata
Title
Modeling to capture bystander-killing effect by released payload in target positive tumor cells
Authors
Jong Hyuk Byun
Il Hyo Jung
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5336-7

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine